Shanghai, China, 12 October 2021 — MicroPort CardioFlow Medtech Corporation (CardioFlow Medtech) announced on 27 September, 2021, that its VitaFlow Liberty™ Transcatheter Aortic Valve and Retrievable Delivery System (VitaFlow Liberty™) was used in surgeries conducted by 19 heart valve teams from 15 hospitals across China on the first day of its market launch. As a next-generation transcatheter aortic valve implantation (TAVI) product, the launch of the VitaFlow Liberty™, initiates a new era of motorized retrievable transcatheters in China’s TAVI Market.
At present, VitaFlow Liberty™ is the only motorized retrievable TAVI system commercially available across the globe. The system’s innovative motorized handle allows for fast, stable and accurate release and retrieval, providing surgeons with better control over the procedure. In addition, it is currently the only delivery system commercially available in the Chinese market that features a 360-degree bendable distal end. This superior flexibility can effectively help minimize blood vessel complication, whilst the bovine pericardium allows for better durability. The valve’s effective double-layer skirts design also helps to better prevent perivalvular leakage.
There are an estimated 25 million patients suffering from valvular heart disease in China [1]. Due to China’s large and aging population, it is expected that the number of patients requiring TAVI treatments will grow exponentially in the near future. Valve intervention technologies are undergoing a radical change in China — a technology that used to be at the cutting-edge is now a mainstream option. As such, CardioFlow Medtech’s engineers are committed to supporting the improvement of both quantity and quality in China’s TAVI field, flattening the learning curve of clinical experts and reducing surgical risks within TAVI operations.
Since its launch two years ago, VitaFlow® has become available in more than 250 heart centers in China. The successful implantation of the VitaFlow Liberty™ in clinical centers across China on the first day of its commercial launch shows that it has the potential to improve the surgical experience and deliver a safe, efficient and consistent treatment for surgeons, improving clinical outcomes for patients.
About CardioFlow Medtech
Founded in 2015, CardioFlow Medtech (stock code: 02160), a subsidiary of MicroPort Scientific Corporation (stock code: 00853), focuses on the research, development and commercialization of innovative transcatheter and surgical solutions for valvular heart diseases. In the future, CardioFlow Medtech will continue to focus on saving lives and improving the quality of life of its patients. CardioFlow Medtech is commited to strengthening its R&D investment, developing core competitiveness through its products, and delivering high-end and innovative total solutions for valve diseases to satisfy the needs of patients both locally and across the globe.
[1] Yang, Y., Wang, Z., Chen, Z. et al. Current status and etiology of valvular heart disease in China: a population-based survey. BMC Cardiovasc Disord 21, 339 (2021). https://doi.org/10.1186/s12872...